On November 21, 2023, Nemaura Medical Inc. proudly announced its successful acquisition of a remarkable $10 million non-dilutive credit facility. This significant milestone will undoubtedly serve as a catalyst for the company’s strategic growth and propel it towards new heights. With the newfound financial flexibility, Nemaura Medical Inc. can now access up to $1 million per month, empowering its expansion plans and ensuring a prosperous future.
Nemaura Medical Inc.
Updated on: 30/11/2023
Debt to equity ratio: Sell
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
We did not find social sentiment data for this stock
There are no analysts data to display
Nordicus Partners Corporation (NMRD) Stock Performance and Analysis on November 21, 2023
On November 21, 2023, NMRD stock had a mixed performance as it opened higher than the previous close but remained within a narrow range throughout the day. The stock opened at $0.26, slightly higher than the previous day’s close of $0.24. The day’s range for the stock was between $0.25 and $0.26. The trading volume for the day was 14,863 shares, which is significantly lower than the average volume of 177,892 shares over the past three months.
NMRD, or Nordicus Partners Corporation, is a health technology company operating in the medical specialties industry. It is based in New York, New York. The company has a market capitalization of $11.2 million.
In terms of earnings growth, NMRD has shown a positive trend. The earnings growth for the company in the last year was +4.28%.
The revenue growth for NMRD in the last year was -84.71%.
The price/sales ratio for NMRD is 289.00.
Looking at the stock’s performance on November 21, 2023, it did not show any significant movement. The stock opened slightly higher than the previous close but did not experience much volatility throughout the day. The trading volume was also relatively low compared to the average volume.
It is important to note that NMRD is operating in the health technology sector, which can be highly competitive and subject to regulatory challenges. Investors should carefully consider these factors and conduct further research before making any investment decisions regarding NMRD stock.
Nemaura Medical Inc (NMRD) Stock Forecast: Potential 3,169.23% Increase and Analysts Consensus to Buy
On November 21, 2023, Nemaura Medical Inc (NMRD) stock had a median target price of $8.50, indicating a potential increase of +3,169.23%. The consensus among investment analysts is to buy the stock. The company reported sales of $200.0K for the current quarter. However, investors should conduct their own research and analysis before making any investment decisions.